Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:17 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 21,471 matching trials from the live ClinicalTrials.gov search.
Filters: Boston, Massachusetts Clear all
Completed Phase 4 Interventional Results available

Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

NCT01563185
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
800 mg ibuprofen/26.6 mg famotidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
New Orleans, Louisiana • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional

Text Messaging Adherence to Stimulant Medication

NCT01967485
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Text- Messaging, Treatment as usual
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 3, 2026, 5:17 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking

NCT07055217
View directory record Official record
Conditions
Repetitive Negative Thinking, Neurofeedback
Interventions
Mindfulness Training, Mindfulness-based Neurofeedback (Real mbNF), Sham mindfulness-based neurofeedback (Sham mbNF)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 2 Interventional Results available

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

NCT01086540
View directory record Official record
Conditions
Systemic Sclerosis-Associated PAH
Interventions
Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
Biological · Other · Diagnostic Test + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 3, 2026, 5:17 PM EST
Active, not recruiting Phase 2 Interventional

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

NCT03071874
View directory record Official record
Conditions
Meningioma
Interventions
AZD2014
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Nov 3, 2026, 5:17 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Terminated Phase 2 Interventional

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

NCT00006482
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Gatos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 2 Interventional

A Phase 2b Study of Zagociguat in Patients With MELAS

NCT06402123
View directory record Official record
Conditions
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mg, zagociguat 30mg, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 1 Interventional

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

NCT01750580
View directory record Official record
Conditions
CANCER, NOS
Interventions
Lirilumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tampa, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Nov 3, 2026, 5:17 PM EST
Terminated Phase 1 Interventional

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

NCT05160558
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
BIIB132, BIIB132-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Nov 3, 2026, 5:17 PM EST
Completed No phase listed Observational Results available

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

NCT01207648
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
Up to 18 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional

Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery

NCT01697878
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity
Interventions
CPAP followed by atmospheric pressure, Atmospheric pressure followed by CPAP
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 4 Interventional Results available

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

NCT03757585
View directory record Official record
Conditions
Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional Results available

Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

NCT03375489
View directory record Official record
Conditions
Lung Cancer
Interventions
Telehealth Palliative Care, In-person Palliative Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional Results available

Repeated-dose Behavioral Intervention to Reduce Opioid Overdose

NCT03838510
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
REBOOT
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 3 Interventional Results available

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

NCT02439320
View directory record Official record
Conditions
Acute Migraine
Interventions
Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Fountain Hills, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Nov 3, 2026, 5:17 PM EST
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea

NCT07600424
View directory record Official record
Conditions
Rosacea, Rosacea, Erythematotelangiectatic, Flushing
Interventions
Transaricular vagus nerve stimulation (taVNS)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Recruiting Not applicable Interventional

Supraglottic Airway for Resuscitation Trial

NCT07150923
View directory record Official record
Conditions
Neonatal Resuscitation, Delivery Room Resuscitation, Positive Pressure Ventilation, Infant, Newborn, Supraglottic Airway, Laryngeal Mask Airways, Implementation Research
Interventions
Enhanced Standard of Care ("Enhanced"), Enhanced Standard of Care ("Enhanced-Plus")
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Days and older
Enrollment
36,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chula Vista, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Terminated Not applicable Interventional

Total Joint Arthroplasty (TJA) Weight Loss Study

NCT05156762
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Knee, Obesity, Morbid
Interventions
Bariatric surgery, Medical weight loss, Patient research surveys, Total joint arthroplasty (TJA), Usual standard of care
Procedure · Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 3, 2026, 5:17 PM EST
Terminated Phase 3 Interventional Results available

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

NCT03948178
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Nov 3, 2026, 5:17 PM EST
Completed Phase 2 Interventional

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

NCT04845178
View directory record Official record
Conditions
Migraine
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Nov 3, 2026, 5:17 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Relaxation Response Training to Treat Hypertension

NCT01263743
View directory record Official record
Conditions
Hypertension
Interventions
Relaxation Response
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Nov 3, 2026, 5:17 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 123 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 5:17 PM EST
Recruiting Not applicable Interventional

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

NCT06608823
View directory record Official record
Conditions
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Interventions
Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System, SAVR
Device
Lead sponsor
JenaValve Technology, Inc.
Industry
Eligibility
Not listed
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
40
States / cities
Burlingame, California • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 5:17 PM EST